Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer

The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease–free survival in patients with HER2-positive early breast cancer.

Gunter von Minckwitz, MD, PhD, presenting results of the trial; photo © ASCO/Scott Morgan 2017

Breast Cancer

Medicaid Restrictions Negatively Impact Poor Breast Cancer Patients

News | June 26, 2017 | Breast Cancer

By Mark L. Fuerst

Limiting Medicaid enrollment has the potential for negative health impacts, in particular among low-income women with a diagnosis of breast cancer, according to a new study.

News | June 26, 2017 | HER2-Positive Breast Cancer, Breast Cancer

By Dave Levitan

A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer.

Many TNBC Patients Unnecessarily Opt for Mastectomy

News | June 16, 2017 | Triple-Negative Breast Cancer, Breast Cancer

By Mark Fuerst

The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer

News | June 14, 2017 | Breast Cancer

By Dave Levitan

Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine.

Four-Gene Signature Identified Triple-Negative Breast Cancer Subgroups

News | June 12, 2017 | Triple-Negative Breast Cancer, Breast Cancer, ASCO Breast Cancer

By Leah Lawrence

The use of a four-gene signature identified a series of subgroups of triple-negative breast cancer, including one subtype that was responsive to platinum-based chemotherapy in the metastatic setting.

Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer

News | June 12, 2017 | ASCO Breast Cancer, Breast Cancer

By Mark Fuerst

For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.

Dual HER2 Blockade Superior to Single Blockade for HER2+/HR+ Breast Cancer

News | June 08, 2017 | ASCO Breast Cancer, Breast Cancer

By Leah Lawrence

Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer.